Safety and efficacy of autoantigen‐specific therapy with 2 doses of alum‐formulated glutamate decarboxylase in children with multiple islet autoantibodies and risk for type 1 diabetes: A randomized clinical trial

Objective Treatments have failed to delay or stop the autoimmune process, preceding onset of type 1 diabetes. We investigated if autoantigen‐specific treatment with alum‐formulated glutamate decarboxylase (GAD‐Alum) was safe and affected progression to type 1 diabetes in children with islet autoimmu...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pediatric diabetes Jg. 19; H. 3; S. 410 - 419
Hauptverfasser:	Elding Larsson, Helena, Lundgren, Markus, Jonsdottir, Berglind, Cuthbertson, David, Krischer, Jeffrey
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Former Munksgaard John Wiley & Sons A/S 01.05.2018 John Wiley & Sons, Inc
Schlagworte:	Aluminum sulfate Autoantibodies Autoimmunity Children Clinical Medicine Clinical trials Diabetes Diabetes mellitus Diabetes mellitus (insulin dependent) Endocrinology and Diabetes Endokrinologi och diabetes GAD‐Alum Glucose Glucose tolerance Glutamate decarboxylase Hematology Immunological tolerance Insulin Insulinoma Intravenous administration Klinisk medicin Medical and Health Sciences Medicin och hälsovetenskap Neuroendocrine tumors Pediatrics Pediatrik prevention Safety Thyroid type 1 diabetes type 1 diabetes autoimmunity GAD-Alum prevention
ISSN:	1399-543X, 1399-5448, 1399-5448
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!